Leukemia Clinical Trials

⁃ Age ≥ 18 years old,;

⁃ Expected survival period ≥ 3 months;

⁃ Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2;

⁃ The diagnosis of AML who received allo-HSCT, and met the following criteria:

‣ A. Diagnostic criteria for relapsed AML: after complete remission (CR), leukemia cells reappeared in peripheral blood or blast cells in bone marrow ≥ 5% (except for other reasons such as bone marrow regeneration after consolidation chemotherapy) or extramedullary leukemia cell infiltration; B. Minimal Residual Disease (MRD) positive only or relapse: Patient is minimal residual disease (MRD) positive, as assessed on bone marrow aspirate (BMA) by Multiparameter Flow Cytometry (MFC) at time of Treatment Eligibility assessment; C. Degree II and above acute graft-versus-host disease did not occur after transplantation; D. Available allogeneic hematopoietic stem cell transplant donors.

• Adequate organ function: A. Liver function: ALT≤3×ULN, AST≤3×ULN, total bilirubin≤2×ULN; B. Coagulation function: international normalized ratio (INR) or activated partial thromboplastin time (APTT) ≤ 1.5×ULN; C. Renal function: serum creatinine≤1.5×ULN or creatinine clearance rate ≥30mL/min; D. Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 45%;

⁃ Women of child-bearing potential and all male participants must use effective methods of contraception for at least 12 months after infusion.;

⁃ Informed Consent/Assent: All subjects must have the ability to understand and the willingness to sign a written informed consent.